Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1579 | Thyroid (non-cancer) | ICEECE2012

Short-term combined treatment with L-thyroxine plus L-triiodothyronine in drops (LT4 plus LT3) in patients with persistent hypothyroidism and malabsorption during replacement therapy with L-T4.

Ippolito S. , Arpaia D. , Peirce C. , Lombardi G. , Biondi B.

The objective of our study was to evaluate the potential benefit of short-term combined treatment with LT4plusLT3 in patients with persistent hypothyroidism and malabsorption. We report ten cases of patients with hypothyroidism secondary to total thyroidectomy, in which high doses of L-T4 (2,7-3.5 mcg/kg/die) were not adequate to normalize thyroid function. TSH was persistently high (from 10 to 100 mU/L) with low serum levels of thyroid hormones.<p class="ab...

ea0029p328 | Cardiovascular Endocrinology and Lipid Metabolism | ICEECE2012

Effect of medical therapy on 24-h blood pressure profile in acromegaly

Sardella C. , Nuzzo A. , Urbani C. , Lombardi M. , Scattina I. , Tomisti L. , Martino E. , Bogazzi F.

To investigate the blood pressure profile (BP) in active acromegaly and the effect of medical treatment of acromegaly on BP circadian rhythm, we studied 21 acromegalics before and after 3–60 months of treatment with somatostatin analogs (15/21) or pegvisomant (5/21) or both (5/21). Ambulatory 24-h BP was recorded. The 24-h mean BP (MBP), the mean systolic BP (SBP) and diastolic BP (DBP), the day-time (day) and night-time (night) MBP, SBP and DBP and the 24-h mean heart ra...

ea0029p852 | Endocrine tumours and neoplasia | ICEECE2012

Effect of dopamine agonists on the tumor size of prolactinomas: are suppressive doses different from those that normalize prolactin serum levels?

Sardella C. , Urbani C. , Lombardi M. , Manetti L. , Cosci C. , Brogioni S. , Marchello A. , Martino E. , Bogazzi F.

Prolactin-secreting (PRL) adenomas are about 40% of all pituitary adenomas. The most important clinical symptoms of PRL excess are gonadal and sexual dysfunction as a result of tumor expansion in patients with macroadenomas. Medical therapy of prolactinomas relies on the use of dopamine agonists which induce normalization of PRL levels and shrinkage of the tumor mass in the majority of patients. The present study evaluated whether doses of dopamine agonist inducing normalizati...

ea0029p125 | Adrenal medulla | ICEECE2012

Pheochromocytoma incidentally discovered after thyroid surgery manifesting dramatic hypertensive crisis induced by metoclopramide

Corsello S. , Ricciato M. , Paragliola R. , Bello G. , Bocci M. , De Crea C. , Raffaelli M. , Lombardi C. , Antonelli M. , Pontecorvi A. , Bellantone R.

Introduction: Metoclopramide is known to exert stimulatory effects on catecholamine secretion, having been used in the past as provocative test in the diagnosis of pheochromocytoma. We describe a patient with an incidentally discovered pheochromocytoma after metoclopramide administration.Case report: A 64 years-old woman underwent total thyroidectomy for multinodular goiter with ‘follicular proliferation Thy 3’ at FNAB of the target nodule. The...

ea0029p847 | Endocrine tumours and neoplasia | ICEECE2012

Clinical and morphological characterization of C cell hyperplastic and neoplastic lesions of thyroid

Lugli F. , Fusco A. , Bianchi A. , Milardi D. , Cimino V. , Piacentini S. , Celico M. , Lanza P. , Raffaelli M. , Lombardi C. , Fadda G. , Bellantone R. , Pontecorvi A. , Rindi G. , De Marinis L.

Introduction: Medullary thyroid carcinoma (MTC) and C cell hyperplasia (CCH) have a variable clinical presentation and prognosis and few data are available on the correlation between immunohistochemical characterization (IIC) and clinical behavior.Aim: We studied the clinical and morphological characterization of CCH and MTC and we evaluated IIC expression of PTTG-1, SSTR2A, VEGFR-1, VEGFR-2 and VEGFR-3 in 23 cases of CCH and/or MTC, correlating it with ...

ea0026p624 | Clinical case reports | ECE2011

17β-hydroxysteroid dehydrogenase type 3 deficiency: a new case of a rare disease with an uncommon gene mutation

Galdiero M , Vitale P , Cariati F , Grasso L F S , Cozzolino A , Simeoli C , Afeltra L , Piscopo C , Rossi R , Melis D , Alviggi C , Lombardi G , Colao A , Pivonello R

Deficiency of 17β-hydroxysteroid dehydrogenase type 3 (17βHSD3), an enzyme converting androstenedione (A) to testosterone (T) in the Leydig cells of the testis, is a rare cause of autosomal recessive 46,XY disorders of sexual development (DSD). A 18-year-old phenotypically female patient presented with primary amenorrhea. She had deep voice, macrocephaly, broad forehead, enlarged nasal tip, macrostomia, facial acne, gynecomastia, left-convex dorsal scoliosis, hypopla...